The Peptide Landscape is Changing: What the Recent FDA Update Means for You.
There has been significant movement in the world of peptide therapy recently. As of April 2026, the FDA has removed several key peptides, including BPC-157, TB-500, and GHK-Cu, from the restrictive Category 2 list.
Why This Matters: For the past two years, many patients were pushed toward unregulated gray-market sources because of these restrictions. The removal of these nominations suggests a reconsideration of the safety data, potentially reopening the doors for licensed compounding pharmacies to provide these high-quality therapeutics more broadly.
The Warning: While this is exciting news, it is not a free-for-all.
Sourcing is Everything: Research Only peptides found online lack quality control and purity guarantees.
Medical Oversight: Peptides like CJC-1295 or Ipamorelin are powerful tools that require precise dosing and professional monitoring to be effective and safe.
The Influx of Influencers: Be careful who you follow and what they recommend.
Not every peptide is created equal that is available to consumers. We remain committed to sourcing only from FDA-registered, U.S.-based regulated pharmacies. If you’ve been waiting for a safer way to access these healing tools, now is the time to start the conversation.
We regularly prescribe peptides and have seen remarkable results with our clients that utilize them including decreased overall inflammation and pain, improved body composition and improved skin texture.
Curious about peptides? Book your peptide consult with us!